A double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).

Affiliation auteurs!!!! Error affiliation !!!!
TitreA double-blind placebo-controlled randomized phase II trial assessing the activity and safety of regorafenib (REG) in patients (pts) with nonadipocytic soft tissue sarcoma (STS) previously treated with pazopanib (PAZ).
Type de publicationJournal Article
Year of Publication2019
AuteursPenel N, Blay J-Y, Wallet J, Ray-Coquard ILaure, Le Cesne A, Ryckewaert T, Italiano A, Salas S, Delcambre C, Bompas E, Bertucci F, Saada-Bouzid E, Chaigneau L, Chevreau C, Thery J, Decoupigny E, Vanseymortier M, Le Deley M-C, Mir O
JournalJOURNAL OF CLINICAL ONCOLOGY
Volume37
Date PublishedMAY 20
Type of ArticleMeeting Abstract
ISSN0732-183X